GOSS · Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

3115 Merryfield Row, San Diego, CA, 92121, United States
Biotechnology
Healthcare

Market Cap

69.91M

52 Wk Range

$8.29 - $309.60

Previous Close

$11.43

Open

$11.24

Volume

143,783

Day Range

$10.80 - $11.85

Enterprise Value

59.51M

Cash

51.19M

Avg Qtr Burn

-29.58M

Insider Ownership

1.44%

Institutional Own.

76.09%

Qtr Updated

Sep 30th 2026